Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
Elevai Labs, Inc. (NASDAQ: ELAB) is a California-based medical aesthetics company that specializes in physician-dispensed skincare products. Elevai leverages cutting-edge science-driven technologies to modernize the aesthetic skincare market. The company has commercialized its proprietary ELEVAI Exosomes, a next-generation, patent-pending technology used in its flagship skincare products.
Recently, Elevai launched an online e-commerce portal, expanding their business-to-business (B2B) relationships to retail customers. This platform allows customers to select a physician provider to start their personalized skincare journey and enjoy the convenience of online re-ordering. The launch supports Elevai’s sales and marketing initiatives, reflecting the company's commitment to providing a medically-guided customer experience.
Elevai also announced unaudited 113% year-over-year (YoY) Q4 sales growth and 75% YoY Q4 new account growth. The company's robust infrastructure enables the quick launch of new products utilizing the same ELEVAI exosome platform technology.
In terms of global expansion, Elevai recently signed an exclusive distribution agreement with ILIA International Ltd. in Taiwan. This partnership is set to distribute ELEVAI’s patented skincare products, leveraging ILIA’s expertise and access to Taiwan's high-end medical aesthetics market. Elevai has secured a total of five international distribution agreements with a cumulative minimum purchase requirement commitment of up to $4.9 million over the next five years.
Elevai Biosciences, a division of the company, is focusing on the development of aesthetic medicines. One of its lead assets, EL-22, is an engineered probiotic aimed at treating obesity by preserving muscle mass while decreasing fat mass. Preclinical studies suggest that EL-22 has the potential to work in combination with GLP-1 receptor agonists like Ozempic and Mounjaro.
Elevai's commitment to innovation and collaboration positions it as a leader in the medical aesthetics industry. The company continues to empower physicians and enhance customer outcomes through its innovative skincare solutions.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has been invited to present at UCLA's exclusive symposium on Anti-Obesity Treatments: Challenges and Emerging Solutions. The company will showcase EL-22, their groundbreaking engineered probiotic designed to preserve muscle mass during weight loss treatments.
The symposium, organized by UCLA Metabolism Theme at David Geffen School of Medicine, brings together leading obesity clinicians, researchers, drug developers, and investors. EL-22 addresses a critical challenge in current obesity treatments, particularly with GLP-1 receptor agonists, where 30-50% of body weight lost is lean muscle mass—a side effect without approved treatments.
The presentation is scheduled for February 7th at 11:30 am PT, where Northstrive Biosciences aims to connect with key opinion leaders, investors, and established pharma companies in the obesity space.
PMGC Holdings Inc. (NASDAQ: ELAB) has completed the divestiture of its wholly owned subsidiary Elevai Skincare Inc. to Carmell The transaction includes:
- Approximately $1.1 million in Carmell common stock (1,267,040 total shares at $0.8488 per share)
- Around $57,000 in cash upon sale of specified inventory
- Assumption of Elevai's contractual liabilities and trade payables
- 5% royalty on net sales from existing products for 5 years
- $500,000 milestone payment if hair/scalp products reach $500,000 in revenue within 24 months
The strategic divestment aims to reduce cash burn and enhance operational efficiency. Following the closing, PMGC's outstanding common stock totals approximately 3.07 million shares.
PMGC Holdings Inc. (NASDAQ: ELAB) has announced the renaming of its wholly owned subsidiaries as part of a strategic realignment. Elevai Research Inc. has been renamed to PMGC Research Inc., which focuses on public-private collaborations leveraging research grants. Elevai Biosciences Inc. has been rebranded as Northstrive Biosciences Inc., a biopharmaceutical company targeting obesity with next-generation treatments. These changes reflect the company's evolution as a diversified holding company.
PMGC Holdings Inc. (NASDAQ: ELAB) has announced the sale of its skincare subsidiary, Elevai Skincare, as part of its strategic transformation. The divestiture will strengthen the company's balance sheet through approximately $1.1 million in Carmell stock and a 5% royalty on skincare revenues over the next five years, plus milestone payments.
The sale reduces operational losses and positions PMGC for new growth opportunities. The company maintains three subsidiaries: Elevai Biosciences, focusing on aesthetic medicines including EL-22 for muscle preservation during weight loss treatments; Elevai Research, utilizing Canadian research grants; and PMGC Capital , a multi-strategy investment vehicle.
The company aims to pursue transformative acquisitions and build a diversified portfolio focused on substantial growth and shareholder value creation.
Carmell (NASDAQ: CTCX) has entered into a definitive agreement to acquire the skincare and haircare business assets of PMGC Holdings Inc. (NASDAQ: ELAB), formerly Elevai Labs Inc. The acquisition terms include:
- $1.1 million in Carmell common stock at closing
- $57,000 in cash for specified inventory
- 5% of net sales from existing products for 5 years
- $500,000 milestone payment if hair/scalp products reach $500,000 in revenue within 24 months
The acquired assets include a product portfolio with $2.5 million trailing twelve-month revenue, commercial and product development team, approximately $1.0 million in inventory, and $0.03 million in accounts receivable. The deal integrates stem cell derived exosome technology into Carmell's bio-aesthetic platform.
PMGC Holdings Inc. (Nasdaq: ELAB), formerly Elevai Labs Inc., announced a strategic reorganization including a name change and redomiciliation from Delaware to Nevada, effective December 23, 2024. The company will maintain its ELAB ticker on Nasdaq. The restructuring reflects an expanded vision to build a portfolio of growth-focused companies.
The portfolio includes four key subsidiaries: Elevai Skincare Inc. (physician-dispensed skincare solutions), Elevai Biosciences Inc. (biopharmaceutical developments), Elevai Research Inc. (life sciences research), and PMGC Capital (multi-strategy investment vehicle). The Nevada redomiciliation aims to benefit from a business-friendly regulatory environment, enhanced director protections, reduced state franchise taxes, and flexible shareholder governance.
Elevai Labs Inc. (Nasdaq: ELAB) announced a strategic reorganization effective December 20, 2024, including a name change to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. The company will continue trading under 'ELAB' on Nasdaq, with changes effective December 23, 2024.
The reorganization reflects an expanded vision to build a portfolio of growth companies. The current portfolio includes Elevai Skincare Inc. (skincare solutions), Elevai Biosciences Inc. (biopharmaceutical developments), Elevai Research Inc. (life sciences research), and PMGC Capital (multi-strategy investment vehicle).
The move to Nevada offers benefits including a business-friendly regulatory environment, enhanced director protections, lower state franchise taxes, and flexible shareholder governance.
Elevai Biosciences, a subsidiary of Elevai Labs, has announced a regulatory pathway for EL-22, a pioneering obesity therapy. EL-22, a first-in-class myostatin asset, aims to preserve muscle mass while reducing fat, addressing muscle loss often seen with GLP-1-based treatments. The company plans to file an Investigational New Drug (IND) application with the FDA in 2025.
Elevai is preparing for a pre-IND meeting with the FDA in Q1 2025 to establish the development pathway for EL-22. This meeting will clarify additional preclinical requirements and adjustments to Chemistry, Manufacturing, and Controls before IND submission. EL-22 has shown significant physiological and functional improvements in preclinical studies and completed a Phase 1 clinical trial in South Korea, demonstrating safety and tolerability in healthy volunteers.
Leveraging data from their Korean partner, Elevai aims to accelerate the IND process and subsequent U.S. clinical trials, potentially redefining obesity care by combining effective weight loss with muscle preservation.
Elevai Labs Inc. (NASDAQ: ELAB) announces the launch of S-Series Root Renewal System, marking its entry into the hair care market through subsidiary Elevai Skincare. The three-part system includes shampoo, conditioner, and serum, featuring proprietary PREx Exosomes™ and Y100™ technologies targeting scalp and hair health at the cellular level.
The system will initially launch through select medical aesthetics partners before a full e-commerce rollout in January 2025. The product combines nano-encapsulated growth factors and AI-discovered molecules supporting mitochondrial function. This marks Elevai Skincare's first new product launch since 2022, with BosleyMD® recognizing Y100 technology as a major innovation in hair loss treatment.
Elevai Labs announces record-breaking sales for its Elevai Skincare division in 2024. The company reported $300K revenue in November 2024, exceeding the previous four months average by 65%. Monthly revenues were: July ($160K), August ($199K), September ($168K), and October ($198K).
The achievement follows transformational restructuring efforts by the new executive team implemented in Q3 2024, focusing on operational efficiency and a performance-driven culture. Key success drivers included sales culture transformation, optimized budgets, improved marketing strategies, and targeted training programs. The company reports reduced operating expenses while achieving higher revenue, demonstrating progress toward positive net profits.
FAQ
What is the current stock price of PMGC Holdings (elab)?
What is the market cap of PMGC Holdings (elab)?
What does Elevai Labs specialize in?
What is the ELEVAI Exosome technology?
How can consumers purchase Elevai products?
What recent achievements has Elevai Labs made?
What is EL-22?
Who is Elevai Biosciences?
What markets does Elevai target with its products?
How does Elevai support its distribution partners?
What is the company's commitment to innovation?
Where can I find more information about Elevai Labs?
